EB
The startup develops plasma-derived therapeutics using its proprietary PlasmaCap EBA technology, which enhances the efficiency and precision of plasma protein extraction. This approach addresses the critical need for accessible and effective therapeutic products for patients requiring plasma-based treatments.
Updated 2 months ago
Funding
$117.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
TC
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops plasma-derived therapeutics using its proprietary PlasmaCap EBA technology, which enhances the efficiency and precision of plasma protein extraction. This approach addresses the critical need for accessible and effective therapeutic products for patients requiring plasma-based treatments.